Multibagger pharma stock that has delivered a return of 1,222 percent in just one year jumps 4 percent in the day’s trade upon receiving an export order from Dubai worth Rs. 169 Crores.
With a market capitalization of Rs. 1,200 Crores, the shares of Remedium Lifecare Limited were trading at Rs. 119, down 2.50 percent from its previous day’s close price of Rs. 122.05. It has delivered multi-bagger returns of 1222 percent in a year.
Remedium Lifecare Limited has received an export order worth Rs. 169 Crores from Pharmyka General Trading LLC a Pharmaceutical Company Situated in UAE, for the supply of pharmaceutical chemicals. The order is to be executed between April 2024 to March 2025.
Remedium Lifecare Limited is engaged in the business of trading and selling API intermediates (KSMs & CRMs) and various other raw materials used in API trading to innovator and generic pharmaceutical players in Domestic and International markets
Its revenue from operations grew by 1.02 percent from Rs. 505 Crores in FY22 to Rs. 510 Crores in FY23, accompanied by increasing profits of Rs. 1 Crore to Rs. 5 Crore.
It has reported a return on equity (ROE) of 71 percent and a return on capital employed (ROCE) of 103 percent, it is making good returns on its equity and capital employed. It has a low debt-to-equity ratio of 0.05.
According to the latest shareholding data available for the December 2023 quarter, the company’s Promoters hold just a 1.11 percent stake, the Foreign Institutional Investors (FII) hold 0.04 percent, and the remaining 98.86 percent is held by the public which is not fundamentally good for the investors.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
